At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed May 14, 2026 at 16:01 ET
Celcuity reported Q1 2026 GAAP EPS of -$0.97, a 9.0% miss vs consensus of -$0.89, with net loss widening to $52.8M from $37.0M a year ago. The key catalyst is the positive Phase 3 VIKTORIA-1 topline data in the PIK3CA mutant cohort, supporting an sNDA submission in Q3 2026 ahead of the July 17 PDUFA date for the wild-type NDA. The stock's move will be driven by the clinical progress and regulatory timeline, not the earnings miss, as the company remains pre-revenue.
- GAAP EPS -$0.97 vs consensus -$0.89 (9.0% miss); net loss $52.8M vs $37.0M YoY
- Phase 3 VIKTORIA-1 PIK3CA mutant cohort met primary endpoint with statistically significant PFS improvement vs alpelisib
- FDA Priority Review for gedatolisib NDA in PIK3CA wild-type ABC; PDUFA date July 17, 2026
- sNDA submission for PIK3CA mutant cohort planned for Q3 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access